A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Exclusion Criteria

• •Transplant: Blood type (ABO)-incompatible transplant.
• •History of multiple organ transplants including en bloc and dual kidney transplants.
• •Acute, rapid decline in renal function, defined as a participant likely to require renal replacement therapy within the subsequent 30 days as determined by the Investigator.
• •Treatment: Prior AMR/TCMR treatment (with the exception of corticosteroids) within 3 months prior to randomization is excluded as listed below. Participants who received any of these treatments between 3 and 6 months prior to randomization must have both a renal biopsy (IC3) and DSA testing at least 6 weeks after completing (or stopping) treatment in order to confirm continuing AMR and to determine eligibility:
• •1. Intravenous or subcutaneous immunoglobulin (IVIg or subcutaneous immunoglobulin \[SCIg\]) or PLEX.
• •2. Complement system inhibitors (e.g., eculizumab).
• •3. Proteasome inhibitors (e.g., bortezomib).
• •4. Tocilizumab.
• •5. Any B cell-depleting therapy (including anti-Cluster of Differentiation 20 \[CD20\] agents \[e.g., rituximab\]) within 3 months prior to randomization.
• •6. Any other investigational agent within 3 months or 5 half-lives (whichever is longer) of randomization.